Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clin...( One-year Data Demonstrate Continued ...),Health

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical

Results with XIENCE V

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically significant clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System at one year, including continued clinical superiority in major adverse cardiac events (MACE) and continued non- inferior rates of target vessel failure (TVF) with XIENCE V compared to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System. The results were presented at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington D.C.

These results follow the data presented earlier this year at the annual American College of Cardiology conference, wherein XIENCE V demonstrated superiority to TAXUS in the SPIRIT III trial on the study's primary endpoint of in-segment late loss at eight months with a statistically significant 50 percent reduction in late loss compared to TAXUS. (In-segment late loss is a measure of vessel renarrowing).

The SPIRIT III clinical trial of 1,002 patients demonstrated the following key results for XIENCE V at one year:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated clinical superiority to TAXUS with a statistically

significant 43 percent reduction in MACE compared to TAXUS at one year.

These MACE results are consistent with the clinically superior 44

percent reduction in MACE observed for XIENCE V at nine months. MACE is

an important clinical measure of safety and efficacy outcomes for

patients, defined as cardiac death, heart attack (myocardial infarction

or MI), or ischemia-driven target lesion revascularization (TLR driven

by lack of blood supply).

--
'/>"/>